Lung Cancer Analysis
🇺🇸 FDAExpert commentary and market intelligence for pharma strategy teams
Showing 1–12 of 13 articles
Merck and Gilead report mixed outcomes in lung cancer and HIV studies
Lenacapavir PrEP shows high HIV-prevention efficacy in Gilead’s Phase 3 trials
AstraZeneca and Daiichi Sankyo datopotamab deruxtecan hits lung cancer endpoint
ASCO Summit: Ivonescimab's China Lung Data Shows Promise, But Global Validation Remains Key
Akeso and Summit Drug Shows Promise in Lung Cancer Trial
Latest Insights on Parkinson’s Drug Setback and Merck’s Lung Cancer Therapy
#ASCO26: Kelun's Phase 3 Lung Cancer Success with Merck
Merck-Kelun Lung Cancer Drug Cuts Tumor Progression Risk by 65%
Osimertinib FDA Approval Expands Early-Stage NSCLC Treatment
KRAS G12C Inhibitors NSCLC: Market Analysis of Sotorasib & Adagrasib
FDA Companion Diagnostic Policies: Market Evolution in Precision Oncology
FDA Approval KRAS G12C NSCLC: Sotorasib & Adagrasib Insights